Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region.

Tytuł:
Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region.
Autorzy:
Schlepckow K; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Monroe KM; Denali Therapeutics Inc., South San Francisco, CA, USA.
Kleinberger G; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Cantuti-Castelvetri L; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Parhizkar S; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Xia D; Denali Therapeutics Inc., South San Francisco, CA, USA.
Willem M; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Werner G; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Pettkus N; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Brunner B; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Sülzen A; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Nuscher B; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Hampel H; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Xiang X; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.; Graduate School of Systemic Neuroscience, Ludwig-Maximilians-Universität München, Munich, Germany.
Feederle R; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Helmholtz Center Munich, German Research Center for Environmental Health, Institute for Diabetes and Obesity, Core Facility Monoclonal Antibody Development, Munich, Germany.
Tahirovic S; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Park JI; Denali Therapeutics Inc., South San Francisco, CA, USA.
Prorok R; Denali Therapeutics Inc., South San Francisco, CA, USA.
Mahon C; Denali Therapeutics Inc., South San Francisco, CA, USA.
Liang CC; Denali Therapeutics Inc., South San Francisco, CA, USA.
Shi J; Denali Therapeutics Inc., South San Francisco, CA, USA.
Kim DJ; Denali Therapeutics Inc., South San Francisco, CA, USA.
Sabelström H; Denali Therapeutics Inc., South San Francisco, CA, USA.
Huang F; Denali Therapeutics Inc., South San Francisco, CA, USA.
Di Paolo G; Denali Therapeutics Inc., South San Francisco, CA, USA.
Simons M; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Institute of Neuronal Cell Biology (TUM-NZB), Munich, Germany.
Lewcock JW; Denali Therapeutics Inc., South San Francisco, CA, USA.
Haass C; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Źródło:
EMBO molecular medicine [EMBO Mol Med] 2020 Apr 07; Vol. 12 (4), pp. e11227. Date of Electronic Publication: 2020 Mar 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2024- : [London] : Nature Publishing Group
Original Publication: Chichester, West Sussex : Wiley-Blackwell
MeSH Terms:
Microglia*/pathology
Multiple Myeloma*
Antibodies, Monoclonal/*pharmacology
Membrane Glycoproteins/*immunology
Receptors, Immunologic/*immunology
Amyloid beta-Peptides ; Animals ; Cell Line, Tumor ; Female ; Macrophages ; Mice ; Rats ; Rats, Wistar
References:
Neurobiol Aging. 2013 Dec;34(12):2890.e1-5. (PMID: 23870839)
Immunity. 2017 Sep 19;47(3):566-581.e9. (PMID: 28930663)
Mol Neurodegener. 2013 Jun 21;8:19. (PMID: 23800361)
J Nucl Med. 2019 Apr;60(4):548-554. (PMID: 30262517)
Sci Transl Med. 2014 Jul 2;6(243):243ra86. (PMID: 24990881)
J Biol Chem. 2008 Jan 11;283(2):677-83. (PMID: 17962197)
Cell. 2019 Jul 25;178(3):686-698.e14. (PMID: 31257031)
J Exp Med. 2017 Mar 6;214(3):597-607. (PMID: 28209725)
J Exp Med. 2018 Mar 5;215(3):745-760. (PMID: 29321225)
N Engl J Med. 2013 Oct 17;369(16):1568-9. (PMID: 24131183)
Neuron. 2017 May 17;94(4):759-773.e8. (PMID: 28521131)
Mol Neurodegener. 2019 Jan 10;14(1):1. (PMID: 30630532)
EMBO Mol Med. 2017 Oct;9(10):1356-1365. (PMID: 28855300)
PLoS One. 2011;6(4):e18556. (PMID: 21602908)
Acta Neuropathol. 2015 Mar;129(3):429-47. (PMID: 25631124)
Neuron. 2014 Jan 8;81(1):49-60. (PMID: 24411731)
EMBO J. 2017 Jul 3;36(13):1837-1853. (PMID: 28559417)
Nature. 1975 Aug 7;256(5517):495-7. (PMID: 1172191)
Cell. 2017 Jun 15;169(7):1276-1290.e17. (PMID: 28602351)
J Biol Chem. 2013 Nov 15;288(46):33027-36. (PMID: 24078628)
Neurobiol Aging. 2014 Mar;35(3):726.e11-9. (PMID: 24119542)
Semin Immunol. 2015 Dec;27(6):410-5. (PMID: 27033414)
Cell. 2015 Mar 12;160(6):1061-71. (PMID: 25728668)
Nat Rev Immunol. 2003 Jun;3(6):445-53. (PMID: 12776204)
Sci Transl Med. 2011 May 25;3(84):84ra44. (PMID: 21613623)
Elife. 2016 Jan 23;5:. (PMID: 26802628)
Sci Transl Med. 2019 Aug 28;11(507):. (PMID: 31462511)
Nature. 2016 Aug 31;537(7618):50-6. (PMID: 27582220)
J Biol Chem. 2018 Aug 10;293(32):12620-12633. (PMID: 29599291)
J Biol Chem. 2010 Jun 4;285(23):17798-810. (PMID: 20348104)
Immunity. 2019 Mar 19;50(3):723-737.e7. (PMID: 30850344)
Nat Neurosci. 2020 Feb;23(2):194-208. (PMID: 31959936)
Neurosci Lett. 2017 Nov 1;660:109-114. (PMID: 28923481)
Cell. 2017 Aug 10;170(4):649-663.e13. (PMID: 28802038)
EMBO Mol Med. 2016 Sep 01;8(9):992-1004. (PMID: 27402340)
EMBO Rep. 2017 Jul;18(7):1186-1198. (PMID: 28483841)
J Immunol. 2006 Sep 15;177(6):3520-4. (PMID: 16951310)
Nat Neurosci. 2014 Jan;17(1):131-43. (PMID: 24316888)
Nature. 2015 Oct 15;526(7573):443-7. (PMID: 26322584)
EMBO Mol Med. 2016 May 02;8(5):466-76. (PMID: 26941262)
Elife. 2020 Jun 08;9:. (PMID: 32510331)
Neurobiol Aging. 2016 Jun;42:217.e1-3. (PMID: 27067662)
Neuron. 2020 Mar 4;105(5):837-854.e9. (PMID: 31902528)
N Engl J Med. 2013 Jan 10;368(2):107-16. (PMID: 23150908)
Nat Neurosci. 2019 Feb;22(2):191-204. (PMID: 30617257)
EMBO Mol Med. 2020 Apr 7;12(4):e11227. (PMID: 32154671)
Neuron. 2019 Sep 4;103(5):820-835.e7. (PMID: 31301936)
Nat Neurosci. 2014 May;17(5):661-3. (PMID: 24728269)
Sci Transl Med. 2016 Dec 14;8(369):369ra178. (PMID: 27974666)
Neurobiol Aging. 2014 Apr;35(4):934.e7-10. (PMID: 24139279)
EMBO Mol Med. 2017 Oct;9(10):1366-1378. (PMID: 28855301)
J Biol Chem. 2012 Jan 20;287(4):2678-88. (PMID: 22134919)
Cell. 1993 Dec 17;75(6):1039-42. (PMID: 8261505)
Science. 2016 Aug 19;353(6301):777-83. (PMID: 27540165)
N Engl J Med. 2019 Apr 11;380(15):1408-1420. (PMID: 30970186)
Neuron. 2017 Apr 19;94(2):237-248. (PMID: 28426958)
Sci Rep. 2019 May 17;9(1):7508. (PMID: 31101881)
EMBO Mol Med. 2019 Jun;11(6):. (PMID: 31122931)
Biotechniques. 1999 May;26(5):818-20, 822. (PMID: 10337468)
Neurobiol Dis. 2007 Jul;27(1):102-7. (PMID: 17560791)
Nat Commun. 2019 Mar 25;10(1):1365. (PMID: 30911003)
Grant Information:
EXC 2145; ID 390857198 SyNergy International Deutsche Forschungsgemeinschaft (DFG); HA1737/16-1 International Deutsche Forschungsgemeinschaft (DFG); ZT-0027 International Helmholtz Association; International Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF); 115976 International Innovative Medicines Initiative (IMI)
Contributed Indexing:
Keywords: Alzheimer's disease; TREM2; amyloid β-peptide; microglia; therapeutic antibody
Substance Nomenclature:
0 (Amyloid beta-Peptides)
0 (Antibodies, Monoclonal)
0 (Membrane Glycoproteins)
0 (Receptors, Immunologic)
0 (Trem2 protein, mouse)
Entry Date(s):
Date Created: 20200311 Date Completed: 20210728 Latest Revision: 20240328
Update Code:
20240329
PubMed Central ID:
PMC7136959
DOI:
10.15252/emmm.201911227
PMID:
32154671
Czasopismo naukowe
Triggering receptor expressed on myeloid cells 2 (TREM2) is essential for the transition of homeostatic microglia to a disease-associated microglial state. To enhance TREM2 activity, we sought to selectively increase the full-length protein on the cell surface via reducing its proteolytic shedding by A Disintegrin And Metalloproteinase (i.e., α-secretase) 10/17. We screened a panel of monoclonal antibodies against TREM2, with the aim to selectively compete for α-secretase-mediated shedding. Monoclonal antibody 4D9, which has a stalk region epitope close to the cleavage site, demonstrated dual mechanisms of action by stabilizing TREM2 on the cell surface and reducing its shedding, and concomitantly activating phospho-SYK signaling. 4D9 stimulated survival of macrophages and increased microglial uptake of myelin debris and amyloid β-peptide in vitro. In vivo target engagement was demonstrated in cerebrospinal fluid, where nearly all soluble TREM2 was 4D9-bound. Moreover, in a mouse model for Alzheimer's disease-related pathology, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced a homeostatic marker, suggesting a protective function by driving microglia toward a disease-associated state.
(© 2020 The Authors. Published under the terms of the CC BY 4.0 license.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies